Commercializing Stem Cell Therapy

So far, we have got to know about the positive applications of these therapies, which are transplanted into the body with living cells to treat, or eliminate the disease from the patient’s body. The most common type of cell therapy is the hematopoietic therapy. Harvested from the donor’s body for the host to develop bone marrow, it is a well-known cell based therapy, with its self-renewal and differentiation capabilities into many cell types.
Stem cell based therapies have the potential to treat numerous disorders, especially blood and immune related disorders. A wide range of these therapies including allogenic cell therapies, autologous therapies, and mesenchymal these therapies has shown a major breakthrough for curing many medical conditions such as sclerosis, spinal cord injury, diabetes and strokes in the clinical trials. More recently, we have the boon of induced pluripotent stem cells, having the same characteristic as adult embryonic stem cells that can be cultured to produce embryonic stem cells. These cells are important for another key reason- tissue engineering.
Over the last few decades, cell therapies have received medical and commercial successes for emerging as a novel therapeutic option for many cellular dysfunctional diseases. If data are to be believed, the global market of stem cell therapy had touched an average of $410 million revenues by 2009, and the market was expected to grow double and reached a total of 100 million people in the US.
And due to its numerous medical benefits, medical companies and research institutes want to bring its clinical applications from bench to bedside.
Although open to many controversies and debate, we have enough evidence to prove that therapy is indeed an effective therapeutic application to address a range of diseases, including cosmetic procedures like hair regrowth, skin redefining and etc.